FibroGen (FGEN) Misses Q2 EPS by 100c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. SPY
10. FISV

Go back to FibroGen (FGEN) Misses Q2 EPS by 100c

FibroGen Reports Second Quarter 2021 Financial Results

August 9, 2021 4:01 PM EDT

 Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis.

Total roxadustat net sales in China of $52.8 million1 by FibroGen and the distribution entity jointly owned by FibroGen and AstraZeneca

Roxadustat Receives Positive Opinion from the CHMP of EMA for Patients with Anemia of CKD

Roxadustat Receives Negative Vote from FDA Advisory Committee for Patients with Anemia of CKD

SAN FRANCISCO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported... More